ELISpot assay
tumor
TUMOR
Circulating tumor-specific T cell responses were assessed by IFN-γ ELISpot after short-term in vitro stimulation of PBMCs with a mixture of eight TERT-derived MHC class II-binding peptides (pool of HLA-DR and HLA-DP-restricted TERT peptidesThe same experiment was conducted after synthesis of 14 neopeptides identified from patient exome analysis and expressed predominantly in the somatic exome (fold change (FC) in favor of tumor and median MT 50% inhibitory concentration (IC